Business Wire

Smiths Detection launches iCMORE algorithms for lithium batteries and dangerous goods for HI-SCAN 10080 XCT

2.7.2020 12:00:00 EEST | Business Wire | Press release

Share

Smiths Detection, a leading detection and security company, has launched iCMORE detection algorithms for lithium batteries and dangerous goods for use by its HI-SCAN 10080 XCT scanner, becoming its first explosive-detection system (EDS) to offer these options. The algorithms enhance the scanner’s detection capabilities by helping identify lithium batteries, flammable liquids and solids, and compressed and liquefied gasses, which can pose a risk should they ignite or explode.

With iCMORE, Smiths Detection can now reliably and accurately detect potentially dangerous lithium batteries, alongside other dangerous goods, across both its conventional X-ray and its EDS technologies. The iCMORE lithium batteries and dangerous goods algorithms are complementary adaptions to existing screening technology.

Although the screening of dangerous goods is not yet mandatory in hold-baggage and air-cargo screening, the increased level of safety for passengers, staff and assets is a key driver for the implementation of this technology. Rechargeable and non-rechargeable lithium batteries – which power everyday devices such as smartphones, tablets, cameras, laptops and power banks – are classified as dangerous goods by the air-transportation industry because of their ability to ignite during flights. Since 2006,1 the US Federal Aviation Administration has recorded more than 260 incidents of smoke, heat, fire or explosion involving lithium batteries in air cargo or baggage. Furthermore, the transporting of flammable liquids and solids as well as compressed and liquefied gasses continues to pose threats to airport operators, airlines and cargo companies.

To be shipped by air, dangerous goods require special treatment and additional declarations according to International Air Transport Association (IATA) regulations. Through automatic object recognition, iCMORE supports image operators by detecting dangerous goods without increasing their workload, as it requires little training and generates very low false-alarm rates.

“As a trusted partner to airports across the world, we are striving to develop new technologies to counteract new and emerging threats,” said Richard Thompson, Global Director Aviation for Smiths Detection. “The iCMORE modules for both lithium batteries and dangerous goods further enhance the HI-SCAN 10080 XCT, streamlining the hold-baggage and air-cargo screening process without burdening operators. Using this technology will not only make aviation safer but can also help prevent costly fines for shipping dangerous goods in a non-compliant way as well as helping safeguard the global supply of goods, which is essential given the need for medical supplies – for example – to be shipped without interruption.”

This launch follows the release of the iCMORE lithium-batteries module for the HI-SCAN 100100V-2is and HI-SCAN 100100T-2is in August 2019 and the HI-SCAN 6040 CTiX for weapons in cabin baggage.

ENDS

About Smiths Detection:

Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 40 years of field-tested experience, we deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.

Our mission is to help make the world a safer place – and do this by using technology to develop innovative solutions and services which protect life, safeguard society and uphold the free flow of trade.

For more information visit http://www.smithsdetection.com.


1 https://www.faa.gov/hazmat/resources/lithium_batteries/media/Battery_incident_chart.pdf

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Enquiries:
Bettina Meurer, Smiths Detection, Global Aviation Marketing Manager –
E: Bettina.Meurer@smithsdetection.com
T: +49 611 9412 189
M: +49 162 2779 760

Sophie Mills, Smiths Detection, Global Communications Manager –
E: Sophie.Mills@smithsdetection.com
T: + 44 (0)73 8423 6474

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 10:00:00 EEST | Press release

ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to operational execution, but organisations cannot scale AI without trust, visibility, and control,” sai

Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 09:00:00 EEST | Press release

Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin

BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release

BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels

Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye